Eli Lilly Moves to Join Lawsuit Over Weight Loss Drug Shortage

Eli Lilly & Co. is seeking to intervene in a legal battle between the FDA and drug compounders over whether its blockbuster diabetes and weight loss drug tirzepatide is still in shortage.

The company filed a motion to intervene Wednesday in a case brought by the Outsourcing Facilities Association and compounding pharmacy FarmaKeio Custom Compounding challenging the Food and Drug Administration’s October 2024 decision that Lilly’s tirzepatide—a diabetes and obesity treatment branded as Mounjaro and Zepbound—is no longer in short supply in the US.

“Against this backdrop, Lilly seeks to intervene as a defendant in this case to protect its ...